PUBLISHER: The Business Research Company | PRODUCT CODE: 1760474
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760474
Autoimmune Gastrointestinal Dysmotility Global Market Report 2025
Autoimmune gastrointestinal dysmotility (AGID) is a rare condition in which the immune system attacks the nerves that control the movement of the digestive tract. This results in slowed or abnormal motility, leading to symptoms such as nausea, bloating, constipation, and intestinal blockage. AGID is often associated with autoimmune diseases or can occur as a paraneoplastic syndrome.
The main treatment options for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications aim to manage the disorder by reducing inflammation and improving digestive tract motility. The drug classes used include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. Diseases linked to autoimmune gastrointestinal dysmotility include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks. They are used by a variety of end-users, including hospitals, clinics, home care settings, and research institutions.
The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports from The Business Research Company that provides autoimmune gastrointestinal dysmotility market statistics, including the autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with the autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including increasing awareness of rare diseases, the rise in underdeveloped diagnostic practices, a growing number of misdiagnoses with other gastrointestinal disorders, the unavailability of targeted therapies, and delays in research progress.
The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to several factors, including the rising prevalence of autoimmune diseases, improvements in diagnostic techniques, increasing healthcare expenditure, the growth of rare disease registries, and better education for clinicians. Key trends during this period include technological advancements in diagnostics, innovations in immunotherapy, developments in neurogastroenterology research, research and development in motility modulators, and the adoption of personalized treatment approaches.
The increasing prevalence of autoimmune disorders is expected to drive the growth of the autoimmune gastrointestinal dysmotility market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, instead of defending them from infections and foreign substances. The rise in autoimmune disorders is mainly attributed to a combination of genetic predisposition and environmental factors, which together disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Autoimmune gastrointestinal dysmotility plays a key role in identifying and managing underlying autoimmune conditions by revealing immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For example, in November 2024, a survey conducted by Versorgungsatlas.de, a Germany-based organization, showed that out of 73,241,305 people surveyed in 2022, around 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61. As a result, the rising prevalence of autoimmune disorders is contributing to the growth of the autoimmune gastrointestinal dysmotility market.
The growing emphasis on personalized medicine is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market moving forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies based on an individual's unique genetic makeup, lifestyle, and environment. The increasing prominence of personalized medicine is largely driven by advancements in genomics, which enable the precise identification of genetic variations and the development of customized treatments. In the case of autoimmune gastrointestinal dysmotility, personalized medicine helps by tailoring therapies to the individual's genetic makeup and specific disease characteristics. This approach not only enhances treatment efficacy but also minimizes side effects, offering more targeted solutions for managing complex gastrointestinal disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. Therefore, the increasing focus on personalized medicine is contributing to the growth of the autoimmune gastrointestinal dysmotility market.
Key players in the autoimmune gastrointestinal dysmotility market are focusing on forming strategic partnerships to offer digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. Strategic partnerships improve care for autoimmune gastrointestinal dysmotility by providing integrated, virtual-first healthcare with multidisciplinary teams, enhancing symptom management, improving access to care, and increasing cost efficiency. For example, in March 2022, Solera Health, a US-based digital health company, partnered with Oshi Health, a US-based virtual gastrointestinal care company, and Vivante Health, a US-based digital health company. This collaboration aims to deliver advanced digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The partnership focuses on improving patient access to specialized care and enhancing the overall effectiveness of treatments for individuals with gastrointestinal disorders.
Major players in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in autoimmune gastrointestinal dysmotility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Autoimmune Gastrointestinal Dysmotility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on autoimmune gastrointestinal dysmotility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for autoimmune gastrointestinal dysmotility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune gastrointestinal dysmotility market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Medications; Surgical Interventions; Dietary Management; Physical Therapy
- 2) By Drug Class: Prokinetic Agents; Anti-Inflammatory Drugs; Immunosuppressive Drugs; Antibiotics
- 3) By Disease Type: Gastroparesis; Chronic Intestinal Pseudo-Obstruction (Cipo); Functional Dyspepsia; Irritable Bowel Syndrome (Ibs); Celiac Disease
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
- 5) By End User: Hospitals; Clinics; Home Care Settings; Research Institutions
- Subsegments:
- 1) By Medications: Immunosuppressants; Corticosteroids; Prokinetic Agents; Antiemetics; Antispasmodics; Antibiotics
- 2) By Surgical Interventions: Gastrostomy; Jejunostomy; Colostomy; Ileostomy; Pyloroplasty; Colectomy
- 3) By Dietary Management: Enteral Nutrition; Parenteral Nutrition; Gluten-Free Diet; Elemental Diet; Small Frequent Meals
- 4) By Physical Therapy: Pelvic Floor Therapy; Abdominal Massage Therapy; Neuromuscular Electrical Stimulation (NMES); Biofeedback Therapy; Respiratory Muscle Training; Postural Training
- Companies Mentioned: AbbVie Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Chugai Pharmaceutical Co. Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Autoimmune Gastrointestinal Dysmotility Market Characteristics
3. Autoimmune Gastrointestinal Dysmotility Market Trends And Strategies
4. Autoimmune Gastrointestinal Dysmotility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Autoimmune Gastrointestinal Dysmotility Growth Analysis And Strategic Analysis Framework
- 5.1. Global Autoimmune Gastrointestinal Dysmotility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Autoimmune Gastrointestinal Dysmotility Market Growth Rate Analysis
- 5.4. Global Autoimmune Gastrointestinal Dysmotility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Autoimmune Gastrointestinal Dysmotility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Autoimmune Gastrointestinal Dysmotility Total Addressable Market (TAM)
6. Autoimmune Gastrointestinal Dysmotility Market Segmentation
- 6.1. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications
- Surgical Interventions
- Dietary Management
- Physical Therapy
- 6.2. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prokinetic Agents
- Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- Antibiotics
- 6.3. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gastroparesis
- Chronic Intestinal Pseudo-Obstruction (Cipo)
- Functional Dyspepsia
- Irritable Bowel Syndrome (Ibs)
- Celiac Disease
- 6.4. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Other Distribution Channels
- 6.5. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Home Care Settings
- Research Institutions
- 6.6. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunosuppressants
- Corticosteroids
- Prokinetic Agents
- Antiemetics
- Antispasmodics
- Antibiotics
- 6.7. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gastrostomy
- Jejunostomy
- Colostomy
- Ileostomy
- Pyloroplasty
- Colectomy
- 6.8. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Enteral Nutrition
- Parenteral Nutrition
- Gluten-Free Diet
- Elemental Diet
- Small Frequent Meals
- 6.9. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pelvic Floor Therapy
- Abdominal Massage Therapy
- Neuromuscular Electrical Stimulation (NMES)
- Biofeedback Therapy
- Respiratory Muscle Training
- Postural Training
7. Autoimmune Gastrointestinal Dysmotility Market Regional And Country Analysis
- 7.1. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market
- 8.1. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Autoimmune Gastrointestinal Dysmotility Market
- 9.1. China Autoimmune Gastrointestinal Dysmotility Market Overview
- 9.2. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Autoimmune Gastrointestinal Dysmotility Market
- 10.1. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Autoimmune Gastrointestinal Dysmotility Market
- 11.1. Japan Autoimmune Gastrointestinal Dysmotility Market Overview
- 11.2. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Autoimmune Gastrointestinal Dysmotility Market
- 12.1. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Autoimmune Gastrointestinal Dysmotility Market
- 13.1. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Autoimmune Gastrointestinal Dysmotility Market
- 14.1. South Korea Autoimmune Gastrointestinal Dysmotility Market Overview
- 14.2. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Autoimmune Gastrointestinal Dysmotility Market
- 15.1. Western Europe Autoimmune Gastrointestinal Dysmotility Market Overview
- 15.2. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Autoimmune Gastrointestinal Dysmotility Market
- 16.1. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Autoimmune Gastrointestinal Dysmotility Market
- 17.1. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Autoimmune Gastrointestinal Dysmotility Market
- 18.1. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Autoimmune Gastrointestinal Dysmotility Market
- 19.1. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Autoimmune Gastrointestinal Dysmotility Market
- 20.1. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market
- 21.1. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market Overview
- 21.2. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Autoimmune Gastrointestinal Dysmotility Market
- 22.1. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Autoimmune Gastrointestinal Dysmotility Market
- 23.1. North America Autoimmune Gastrointestinal Dysmotility Market Overview
- 23.2. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Autoimmune Gastrointestinal Dysmotility Market
- 24.1. USA Autoimmune Gastrointestinal Dysmotility Market Overview
- 24.2. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Autoimmune Gastrointestinal Dysmotility Market
- 25.1. Canada Autoimmune Gastrointestinal Dysmotility Market Overview
- 25.2. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Autoimmune Gastrointestinal Dysmotility Market
- 26.1. South America Autoimmune Gastrointestinal Dysmotility Market Overview
- 26.2. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Autoimmune Gastrointestinal Dysmotility Market
- 27.1. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Autoimmune Gastrointestinal Dysmotility Market
- 28.1. Middle East Autoimmune Gastrointestinal Dysmotility Market Overview
- 28.2. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Autoimmune Gastrointestinal Dysmotility Market
- 29.1. Africa Autoimmune Gastrointestinal Dysmotility Market Overview
- 29.2. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Company Profiles
- 30.1. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape
- 30.2. Autoimmune Gastrointestinal Dysmotility Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Autoimmune Gastrointestinal Dysmotility Market Other Major And Innovative Companies
- 31.1. Zeria Pharmaceutical Co. Ltd.
- 31.2. Ironwood Pharmaceuticals Inc.
- 31.3. Vanda Pharmaceuticals Inc.
- 31.4. Dr. Falk Pharma GmbH
- 31.5. Rose Pharma LLC
- 31.6. Parvus Therapeutics Inc.
- 31.7. CinDome Pharma Inc.
- 31.8. Neurogastrx Inc.
- 31.9. Renexxion LLC
- 31.10. ISOThrive Inc.
- 31.11. Ambrose Healthcare Inc.
- 31.12. AnTolRx Inc.
- 31.13. Enteralia Bioscience S.r.l.
- 31.14. Immunic Inc.
- 31.15. Mozart Therapeutics Inc.
32. Global Autoimmune Gastrointestinal Dysmotility Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Autoimmune Gastrointestinal Dysmotility Market
34. Recent Developments In The Autoimmune Gastrointestinal Dysmotility Market
35. Autoimmune Gastrointestinal Dysmotility Market High Potential Countries, Segments and Strategies
- 35.1 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
